Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ALK |
Variant | R1209Q |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | ALK R1209Q lies within the protein kinase domain of the Alk protein (UniProt.org). R1209Q leads to decreased cell proliferation and cell viability compared to wild-type Alk in one of two cell lines in culture (PMID: 29533785), but has not been biochemically characterized, and therefore, its effect on Alk protein function is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
ALK mutant ALK R1209Q |
Transcript | NM_004304.5 |
gDNA | chr2:g.29220725C>T |
cDNA | c.3626G>A |
Protein | p.R1209Q |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004304.4 | chr2:g.29220725C>T | c.3626G>A | p.R1209Q | RefSeq | GRCh38/hg38 |
NM_004304 | chr2:g.29220725C>T | c.3626G>A | p.R1209Q | RefSeq | GRCh38/hg38 |
NM_004304.5 | chr2:g.29220725C>T | c.3626G>A | p.R1209Q | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK R1209Q | colon cancer | predicted - sensitive | Crizotinib + Pazopanib | Case Reports/Case Series | Actionable | In a Phase I trial, Xalkori (crizotinib) and Votrient (pazopanib) combination treatment resulted in a partial response in a patient with colon cancer harboring ALK R1209Q (PMID: 33994796; NCT01548144). | 33994796 |